Neurofit, a specialized company in AI solutions for brain disease imaging, announced on the 2nd that it participated in the 2023 European Congress of Radiology (ECR 2023) held in Vienna, Austria.
At this conference, Neurofit showcased its brain neurodegeneration imaging analysis software ‘Neurophet AQUA,’ which has obtained European CE certification, along with the PET automatic imaging analysis software ‘Neurophet SCALE PET,’ the brain electrical stimulation imaging treatment planning software ‘Neurophet tES LAB,’ and the cloud-based brain imaging analysis AI platform ‘Neurophet SegPlus.’
Neurophet AQUA is a medical device brain imaging analysis software that analyzes brain atrophy and white matter degeneration observed in degenerative brain diseases such as Alzheimer’s disease and vascular dementia. Neurophet SCALE PET is an AI-based automatic brain imaging analysis software that quantitatively analyzes Alzheimer’s disease biomarkers by combining PET (positron emission tomography) images and MRI (magnetic resonance imaging).
Using its flagship products Neurophet AQUA and Neurophet SCALE PET, Neurofit is currently conducting the national research project ‘ATNV Project.’ The ATNV Project quantifies Alzheimer’s disease biomarkers ‘Amyloid (A) - Tau (T) - Neurodegeneration (N) - Vascular neuropathology (V)’ through AI imaging analysis technology to identify the type and stage of dementia.
Neurofit expects the ATNV Project to play a key role not only in Alzheimer’s disease diagnosis and prognosis prediction but also in dementia drug development and prescription fields.
Leqembi, an Alzheimer’s disease treatment that received accelerated approval from the U.S. Food and Drug Administration (FDA) in January, is a new drug that removes beta-amyloid protein accumulated in the brain but has the issue of causing ‘ARIA (amyloid-related imaging abnormalities),’ a side effect of anti-amyloid antibody therapy. Monitoring and managing ARIA is essential when prescribing anti-amyloid antibody treatments, and Neurofit believes that its ATNV Project technology will enable analysis of ARIA.
In the ATNV Project, ‘V’ refers to the technology that quantifies vascular neuropathology in brain imaging. It is expected to enable differentiation and monitoring of ARIA through analysis of ARIA-E (edema), mainly found in T2-FLAIR images of brain MRI, and ARIA-H (microbleeds), mainly found in GRE or SWI images.
Jun-Gil Bin, CEO of Neurofit, stated, “To observe the therapeutic effects of Leqembi and avoid side effects, brain imaging must be performed before and after prescription, and the images must be analyzed precisely. The ATNV Project provides a solution that quantitatively measures Alzheimer’s disease-related imaging biomarkers, which is expected to greatly assist in the effective use of Alzheimer’s disease treatments.”
He added, “The vascular neuropathology quantification technology developed by Neurofit for analyzing white matter degeneration and ARIA-H can also be applied to the diagnosis of multiple sclerosis, and we are currently advancing this technology. At this European Congress of Radiology, we promoted our flagship products and the ATNV Project and held discussions with global medical institutions and dementia drug developers to find collaboration partners for brain imaging analysis business and dementia drug development support projects.”
Meanwhile, ECR is the largest European radiology conference attended by radiologists and medical device industry professionals worldwide. ECR 2023 started on the 1st local time in Austria and will continue until the 5th.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
